The Humira story was of particular interest to me for 2 reasons.
1. It was so widely accepted and was quite a breakthrough in an area with sketchy results. There were many drugs out there that worked but had varying degrees of bad side effects and limited time period that they could be used effectively. Humira was a game changer. It not only worked for varying psoriatic conditions but was well tolerated. They could name their price and did! Quite expensive but very effective. It makes sense Leronlimab is following their playbook to success. Yes, it's a loooong road and we are closer to passing the 7th inning stretch than the 9th inning but as they knew, we also have a lot of the findings that tell us we have may have the same widely accepted, well tolerated molecule that will be a game changer.
2. I was in on the original psoriatic psoriasis study back in the early 2000's and remember what a difference it made in my life. I couldn't stop gushing about this incredible new drug that allowed me to live a normal life and started inquiring about the stock knowing what it's potential was. Look at ABBV chart before Humira and after.....good indicator of what could happen if the company avoids more costly mistakes and follows the path. Basically there is no ABBV before Humira. Excellent molecule, correct mgmt in place, game-plan, finances, and some luck......
Saying this, we obviously have some way to go and correct mgmt is a priority in any company and is one of the top priorities in getting this to the next level. It seems to me Cytodyn has learned some of the lessons that a startup has had to persevere in order to move forward. Unfortunately these lessons come at a steep price and personal preferences needed to be abandoned for the good of the whole. I am encouraged by the latest webcast and am looking forward to the next quarterly update with renewed but guarded enthusiasm. It will be a long road still but knowing we may be on a road that is smoothing out more with each refinement in its process is somewhat comforting for a change. GLTA
1. It was so widely accepted and was quite a breakthrough in an area with sketchy results. There were many drugs out there that worked but had varying degrees of bad side effects and limited time period that they could be used effectively. Humira was a game changer. It not only worked for varying psoriatic conditions but was well tolerated. They could name their price and did! Quite expensive but very effective. It makes sense Leronlimab is following their playbook to success. Yes, it's a loooong road and we are closer to passing the 7th inning stretch than the 9th inning but as they knew, we also have a lot of the findings that tell us we have may have the same widely accepted, well tolerated molecule that will be a game changer.
2. I was in on the original psoriatic psoriasis study back in the early 2000's and remember what a difference it made in my life. I couldn't stop gushing about this incredible new drug that allowed me to live a normal life and started inquiring about the stock knowing what it's potential was. Look at ABBV chart before Humira and after.....good indicator of what could happen if the company avoids more costly mistakes and follows the path. Basically there is no ABBV before Humira. Excellent molecule, correct mgmt in place, game-plan, finances, and some luck......
Saying this, we obviously have some way to go and correct mgmt is a priority in any company and is one of the top priorities in getting this to the next level. It seems to me Cytodyn has learned some of the lessons that a startup has had to persevere in order to move forward. Unfortunately these lessons come at a steep price and personal preferences needed to be abandoned for the good of the whole. I am encouraged by the latest webcast and am looking forward to the next quarterly update with renewed but guarded enthusiasm. It will be a long road still but knowing we may be on a road that is smoothing out more with each refinement in its process is somewhat comforting for a change. GLTA
10
